Complementary IMAC enrichment methods for HLA-associated phosphopeptide identification by mass spectrometry
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Phosphorylation events within cancer cells often become dysregulated, leading to oncogenic signaling and abnormal cell growth. Phosphopeptides derived from aberrantly phosphorylated proteins that are presented on tumors and not on normal tissues by human leukocyte antigen (HLA) class I molecules are promising candidates for future cancer immunotherapies, because they are tumor specific and have been shown to elicit cytotoxic T cell responses. Robust phosphopeptide enrichments that are suitable for low input amounts must be developed to characterize HLA-associated phosphopeptides from clinical samples that are limited by material availability. We present two complementary mass spectrometry–compatible, iron(III)-immobilized metal affinity chromatography (IMAC) methods that use either nitrilotriacetic acid (NTA) or iminodiacetic acid (IDA) in-house-fabricated columns. We developed these protocols to enrich for subfemtomole-level phosphopeptides from cell line and human tissue samples containing picograms of starting material, which is an order of magnitude less material than what is commonly used. In addition, we added a peptide esterification step to increase phosphopeptide specificity from these low-input samples. To date, hundreds of phosphopeptides displayed on melanoma, ovarian cancer, leukemia and colorectal cancer have been identified using these highly selective phosphopeptide enrichment protocols in combination with a program called 'CAD Neutral Loss Finder' that identifies all spectra containing the characteristic neutral loss of phosphoric acid from phosphorylated serine and threonine residues. This methodology enables the identification of HLA-associated phosphopeptides presented by human tissue samples containing as little as nanograms of peptide material in 2 d.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“most immunopeptidomic laboratories do not routinely add a cysteine protecting reagent during cell lysis for MHC-IAC.7,8,18,24,27,49,54−57”
From Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome (2021) · cites this paper as [54]
In the citing paper
“Most immunopeptidomic studies either do not consider cysteine modifications18,22,52,54−56 or use cysteinylation as the only cysteine modification allowed in database searches.7,24,27,57”
From Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome (2021) · cites this paper as [54]
In the citing paper
“This approach can yield substantial quantities of HLA-peptide complexes that can be easily purified from the medium before nUPLC-MS/MS analysis.”
From Mass spectrometry–based identification of MHC-bound peptides for immunopeptidomics (2019) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry
Syka, J. E. P., Coon, J. J., Schroeder, M. J., Shabanowitz, J., & Hunt, D. F. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402700101 · Cited by 2,370
Self-citationTowards a systems understanding of MHC class I and MHC class II antigen presentation
Neefjes, J., Jongsma, M. L. M., Paul, P., & Bakke, O. (2011) · Nature Reviews Immunology · doi:10.1038/nri3084 · Cited by 2,044
Zarling, A. L., Ficarro, S. B., White, F. M., Shabanowitz, J., Hunt, D. F., & Engelhard, V. H. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.12.1755 · Cited by 213
Self-citationMohammed, F., Cobbold, M., Zarling, A. L., Salim, M., Barrett-Wilt, G. A., Shabanowitz, J., Hunt, D. F., Engelhard, V. H., & Willcox, B. E. (2008) · Nature Immunology · doi:10.1038/ni.1660 · Cited by 155
Self-citation
Cited by
Bassani-Sternberg, M., Bräunlein, E., Klar, R., Engleitner, T., Sinitcyn, P., Audehm, S., Straub, M., Weber, J., Slotta-Huspenina, J., Specht, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms13404 · Cited by 693
Mass spectrometry–based identification of MHC-bound peptides for immunopeptidomics
Purcell, A. W., Ramarathinam, S. H., & Ternette, N. (2019) · Nature Protocols · doi:10.1038/s41596-019-0133-y · Cited by 394
Phosphoproteomics in the Age of Rapid and Deep Proteome Profiling
Riley, N. M., & Coon, J. J. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.5b04123 · Cited by 265
Sturm, T., Sautter, B., Wörner, T. P., Stevanović, S., Rammensee, H.-G., Planz, O., Heck, A. J. R., & Aebersold, R. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00386 · Cited by 63
Zhang, B., & Bassani-Sternberg, M. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007073 · Cited by 44
Metadata
- Authors
- Abelin, J. G., Trantham, P. D., Penny, S. A., Patterson, A. M., Ward, S. T., Hildebrand, W. H., Cobbold, M., Bai, D. L., Shabanowitz, J., & Hunt, D. F.
- Venue
- Nature Protocols
- Published
- 2015-08-06
- Volume
- 10
- Issue
- 9
- Pages
- 1308-1318
- ISSN
- 1750-2799 (ISSN-L)
- 1754-2189
- OpenAlex
- W1192100766
- Cited by
- 82
- References
- 4
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Complementary IMAC enrichment methods for HLA-associated phosphopeptide identification by mass spectrometry. https://app.cochat.ai/papers/10.1038/nprot.2015.086
- The paper
- Abelin, J. G., Trantham, P. D., Penny, S. A., Patterson, A. M., Ward, S. T., Hildebrand, W. H., Cobbold, M., Bai, D. L., Shabanowitz, J., & Hunt, D. F. (2015). Complementary IMAC enrichment methods for HLA-associated phosphopeptide identification by mass spectrometry. Nature Protocols. https://doi.org/10.1038/nprot.2015.086
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.